

Review Form 1.7

Journal Name:	International Journal of Research and Reports in Hematology
Manuscript Number:	Ms_IJR2H_99345
Title of the Manuscript:	Minocycline-induced diplopia in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL): A case report.
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journalijr2h.com/index.php/IJR2H/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments 1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript) 2. Is the title of the article suitable? (If not please suggest an alternative title) 3. Is the abstract of the article comprehensive? 4. Are subsections and structure of the manuscript appropriate? 5. Do you think the manuscript is scientifically correct? 6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form. (Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)	1. Yes 2. Yes 3. Yes 4. Yes 5. Yes 6. yes	
Minor REVISION comments 1. Is language/English quality of the article suitable for scholarly communications?	Yes	
Optional/General comments	Please use acronyms in the text after entering them the first time (see introduction) Please insert also MDR before XDR in the abstract Please write in italics <i>Escherichia coli</i> (Abstract) Please explain what R-Hyper CVAD is (Introduction) - Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone)? Please write Dasatinib not in capital letter "dasatinib"	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Review Form 1.7

Reviewer Details:

Name:	Irene Scagnol
Department, University & Country	Italy